Polynovo Keeps Bull Despite Revenue Miss

Dow Jones07-27 09:22

0122 GMT - PolyNovo keeps its bull at Macquarie despite the wound-treatment specialist missing FY 2026 revenue expectations. The investment bank maintains an outperform rating on the ASX-listed device maker, with analyst Shane Ponraj flagging a stronger-than-anticipated jump in annual cash flow from operations to A$24 million, from A$3 million. With a solid balance sheet and capital-expenditure requirements for PolyNovo's new manufacturing facility largely complete, Ponraj reckons that the company is now well-placed to invest in marketing. He expects ongoing strong order growth. Macquarie cuts its target price 26% to 1.30 Australian dollars. Shares are down 2.3% at A$0.835. (stuart.condie@wsj.com)

 

(END) Dow Jones Newswires

July 26, 2026 21:22 ET (01:22 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment